TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate

June 28, 2023 at 15:49 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

TransCode Therapeutics CEO Michael Dudley joined Proactive's Natalie Stoberman to share the latest progress from its lead RNA oncology candidate TTX-MC138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.

The company has created a platform of drug candidates designed to target a variety of tumour types with the objective of significantly improving patient outcomes. TransCode's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totalling over nine million per year worldwide.

Contact Details

Proactive USA

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/transcode-therapeutics-making-preclinical-progress-with-lead-metastatic-cancer-candidate-175829166

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	260.74	-1.33 (-0.51%)
AAPL	309.18	-1.16 (-0.38%)
AMD	478.47	+21.73 (4.76%)
BAC	62.24	-0.09 (-0.14%)
GOOG	342.44	-2.15 (-0.62%)
META	562.48	+3.46 (0.62%)
MSFT	489.71	+2.40 (0.49%)
NVDA	210.58	+2.10 (1.01%)
ORCL	144.75	+2.30 (1.61%)
TSLA	351.24	+2.29 (0.65%)

Symbol

Price

Change (%)

AMZN

260.74

-1.33 (-0.51%)

AAPL

309.18

-1.16 (-0.38%)

AMD

478.47

+21.73 (4.76%)

BAC

62.24

-0.09 (-0.14%)

GOOG

342.44

-2.15 (-0.62%)

TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate

Contact Details

More News

Recent Quotes